盘龙药业: 关于修订公司章程及制定、修订部分公司治理制度的公告

Core Viewpoint - The company, Shanxi Panlong Pharmaceutical Group Co., Ltd., is revising its Articles of Association and related corporate governance systems to enhance governance efficiency and streamline management processes, including the abolition of the supervisory board and the transfer of its responsibilities to the audit committee of the board of directors [1][2][3]. Summary by Sections Revision of Articles of Association - The company plans to amend its Articles of Association to comply with the latest regulatory framework and improve governance effectiveness [1][2]. - The supervisory board will be dissolved, and its functions will be transferred to the audit committee, pending approval from the shareholders' meeting [1][2]. Specific Amendments - The amendments will include changes to the roles and responsibilities of the board of directors and the legal representative of the company [4][5]. - The new provisions will clarify that the legal representative's civil activities will be the company's responsibility, and the company can seek compensation from the legal representative if damages occur due to their duties [4][5]. Governance Structure Changes - The supervisory board's responsibilities will cease upon the approval of the revised Articles of Association, and the rules governing the supervisory board will be abolished [2][3]. - The company will ensure that the audit committee will diligently perform its supervisory functions until the shareholders' meeting approves the changes [2][3]. Legal Compliance - The revisions are in accordance with the Company Law, Securities Law, and relevant regulations from the Shenzhen Stock Exchange [3][4]. - The company emphasizes that the amendments aim to protect the rights and interests of shareholders, employees, and creditors while ensuring compliance with legal requirements [1][2].